PARP Inhibitors in Colorectal Malignancies: A 2023 Update

CONCLUSION: Efforts to precisely define the homologous repair deficiency (HRD) in CRC - and eventually the subgroup of patients that are expected to benefit the most - are also underway.REGISTRATION NUMBER: DOI: dx.doi.org/10.17504/protocols.io.dm6gp3ey8vzp/v1.PMID:38058097 | DOI:10.2174/0115748871260815231116060817

Source: Reviews on Recent Clinical Trials - December 7, 2023 Category: Cancer & Oncology Authors: Nikolaos Skouteris Georgios Papageorgiou Source Type: research